Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Tools Previous | All Articles This Week | Next
This article originally posted 28 June, 2005 and appeared in  Issue 266

SYMLIN® (pramlintide acetate) Injection

Instruction Sheet Overview.
Advertisement
Symlin® injection is an antihyperglycemic drug for use in patients with diabetes treated with insulin. Pramlintide is a synthetic analog of human amylin, a naturally occurring neuroendocrine hormone synthesized by pancreatic beta cells that contributes to glucose control during the postprandial period. It shows great potential in helping our patients but there are some things you should know about dosing and the use of proper syringes.

The dosing instructions are different for Type 1 and Type 2 patients. In addition the way prescriptions need to be written may be confusing to the patient, the physician and the pharmacist.

Symlin® is measured in mcg(micrograms) and most of us are used to measuring insulin in units. So we must be very careful to be clear as to the doses we want to use. Prescriptions must be written with the mcg designation after the dose. It is important to remember that 6mcg of Symlin® is volume equivalent to 1 unit of insulin.

The starting dose for a type 1 patient is 15mcg which is volume equivalent to 2.5 units of insulin. This is a very small amount and would be impossible to accurately dose in a 1cc(100 unit) syringe.
We need to be sure we order 3/10 cc syringes for our Symlin® patients and explain the dosing to them.

In a study published by Bell DS, et al. in the Arch Intern Med. 1991;151:2265-2269 there was a 43% error among medical professionals in accurately drawing 2 units into a 1cc(100 unit syringe) and a 19% error when drawing 5 units. This could significantly increase hypoglycemia in patients due to the Black box warning (see below).

The starting dose for an insulin using type 2 patient is 60mcg. This would be the equivalent volume of 10 units of insulin and this is titrated to 120mcg as tolerated. As you can see, if the prescriber, pharmacist or patient misinterpret the directions of units vs. mcg, severe problems can develop.

Patients are also suppose to decrease preprandial, rapid-acting or short-acting insulin dosages, including fixed-mix insulins (70/30) by 50% and monitor blood glucose frequently, including pre- and post-meals and at bedtime;

The manufacturer has prepared excellent “Starting Smart with Symlin” instruction sheets for both type 1 and type 2 patients and we have included them for you to print and use with your patients
Symlin_PI_and_Med_Guide.pdf
Symlin type2.pdf
Symlin type1 .pdf

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 28 June, 2005 and appeared in  Issue 266

Past five issues: Diabetes Clinical Mastery Series Issue 137 | Issue 677 | SGLT2 Special Edition Issue 2 | Diabetes Clinical Mastery Series Issue 136 | Issue 676 |

2013 Most Popular Articles:

AACE Releases New Comprehensive Diabetes Management Algorithm
Posted April 25, 2013
AACE - New Diabetes Guidelines Based on Tailored Approach
Posted May 09, 2013
Discovery Raises Hope for Type 1 Diabetes Reversal
Posted May 03, 2013
Diabetes Increases Cancer Risk by 20 Percent
Posted May 16, 2013
AACE: Ralph A. DeFronzo, MD -- Diabetes Prevention Supports More Aggressive and Earlier Intervention
Posted May 09, 2013
AACE – New Test Efficiently Detects Diabetic Neuropathy
Posted May 09, 2013
Intermittent Fasting May Improve Diabetes and Reduce Cardiovascular Risk
Posted May 03, 2013
AACE: CAD Risk for Pre-Diabetes Similar to Diabetes
Posted May 09, 2013
Low-Glycemic Diet Seen to Reverse Diastolic Dysfunction of Diabetes
Posted May 03, 2013
How Type 2 Diabetes Develops
Posted May 16, 2013

See more most popular…


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |
 
Diabetes In Control Advertisers
 
Cast Your Vote
What test do you use to screen for prediabetes?

Navigate Diabetes In Control



Search Articles On Diabetes In Control